This project is funded by:
Epigenetic modifications, including DNA methylation, influence gene regulation involved in hypertension (high blood pressure). This project aims to investigate specific epigenetic changes in obese, non-diabetic individuals undergoing structured weight loss interventions (both surgical and pharmacological e.g. Ozempic, Wegovy). Obesity is a major risk factor for hypertension, yet not all obese individuals exhibit the same blood pressure profiles, suggesting epigenetic factors may influence their cardiovascular risk. However, limited research has explored the specific epigenetic changes that occur in non-diabetic, obese individuals during weight loss and how these might serve as targets for antihypertensive interventions. Understanding these changes can offer insight into novel epigenetic targets for managing hypertension associated with obesity.
This project will recruit obese, non-diabetic adults undergoing different surgical and pharmacological weight loss interventions who will undergo clinical assessment and blood sample collection at baseline, post-intervention and one year follow-up. Epigenetic profiling will examine DNA methylation focusing on genes regulating vascular tone, inflammation and endothelial function. Bioinformatic analysis will be used to detect changes in biological age following treatments and correlate epigenetic data with blood pressure and metabolic profiles. Machine learning models will identify specific epigenetic signatures predictive of improved blood pressure control following weight loss, and pathway analysis will highlight potential therapeutic targets. Identified epigenetic changes will be functionally validated in vascular smooth muscle cell models to determine their impact on blood pressure-regulating genes. Pharmacological modulation of these epigenetic markers will be tested to assess their potential as antihypertensive targets.
This study aims to advance our understanding of how epigenetic changes influence blood pressure and identify novel epigenetic targets for antihypertensive therapies and development of a more personalized approach to hypertension management in obese individuals.
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Biomedical Sciences, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission. If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship. In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
Our fully funded PhD scholarships will cover tuition fees and provide a maintenance allowance of £19,237 (tbc) per annum for three years (subject to satisfactory academic performance). A Research Training Support Grant (RTSG) of £900 per annum is also available.
These scholarships, funded via the Department for the Economy (DfE) and the Vice Chancellor’s Research Scholarships (VCRS), are open to applicants worldwide, regardless of residency or domicile.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
Due consideration should be given to financing your studies.
1.Amenyah SD, Ward M, McMahon A, Deane J, McNulty H, Hughes C, Strain JJ, Horigan G, Purvis J, Walsh CP, Lees-Murdock DJ. (2021) DNA methylation of hypertension-related genes and effect of riboflavin supplementation in adults stratified by genotype for the MTHFR C677T polymorphism. Int J Cardiol. 322, 233-239. This study provides the first RCT evidence that DNA methylation of hypertension-related genes is influenced by gene-nutrient interaction, providing some insight into mechanisms linking hypertension with the genotype-specific response of BP and nutrition
2. Khan, S., & Reddy, P. H. (2015). Epigenetics in aging and metabolic diseases. Aging and Disease, 6(2), 80-94. Explores the role of epigenetic changes in metabolic diseases and aging, particularly relevant to how weight loss in obese individuals may impact epigenetic regulation linked to metabolic and vascular health.
3.Carneiro, G., Dias, M. M., & Rizzo, E. L. (2020). Epigenetic regulation of gene expression in cardiovascular diseases. Archives of Cardiovascular Diseases, 113(3), 173-187. Study on how epigenetic modifications influence gene expression in cardiovascular diseases, which is useful for understanding how these mechanisms might apply to blood pressure regulation in obese individuals.
4.de Mello, V. D., & Pulkkinen, L. (2016). Antihypertensive effects of weight loss: The role of the gut microbiota and epigenetic modifications. Frontiers in Pharmacology, 7, 308. This paper reviews how weight loss can have antihypertensive effects and discusses the role of epigenetics, making it a foundational source for understanding the relationship between weight reduction, blood pressure, and epigenetic changes.
5.van Dijk, S. J., Molloy, P. L., Varinli, H., Morrison, J. L., & Muhlhausler, B. S. (2015). Epigenetics and human obesity. International Journal of Obesity, 39(1), 85-97. Comprehensive overview of epigenetic mechanisms in obesity, covering methylation, histone modifications, and non-coding RNAs, and their impact on weight-related health outcomes.
6.Wahl, S., Drong, A., Lehne, B., et al. (2017). Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature, 541(7635), 81-86. Epigenome-wide association study (EWAS) investigates the relationship between BMI and epigenetic changes, offering evidence for how obesity influences epigenetic patterns that could be relevant to blood pressure regulation.
7.Makar, K. W., Poole, E. M., & Bendich, A. J. (2020). The role of epigenetics in hypertension and antihypertensive drugs. Epigenomics, 12(8), 655-667. Explores the relationship between epigenetics and hypertension, including how epigenetic mechanisms might influence response to antihypertensive treatments, supporting the proposal's exploration of novel therapeutic targets.
8.Huang, T., Shu, Y., Cai, Y. D., & Tu, X. (2018). Epigenetic networks for obesity. Medicine, 97(52), e13889. This paper discusses how epigenetic networks are interconnected in obesity, making it valuable for understanding the multi-level regulation that might also affect hypertension-related genes.
Submission deadline
Monday 24 February 2025
04:00PM
Interview Date
24 March - 4 April 2025
Preferred student start date
15 September 2025
Telephone
Contact by phone
Email
Contact by email